ADIAL PHARMACEUTICALS, INC. 8-K

What Happened

• Adial Pharmaceuticals, Inc. (ticker: ADIL) announced it received a Notification Letter from Nasdaq’s Listing Qualifications Department on February 23, 2026, confirming the company regained compliance with Nasdaq Listing Rule 5550(a)(2).
• Nasdaq determined ADIL’s closing bid price was $1.00 or greater for 10 consecutive business days (February 6, 2026 through February 20, 2026). The company issued a press release on February 24, 2026 and filed the 8-K the same day.

Key Details

• Nasdaq compliance restored under Listing Rule 5550(a)(2) after the 10-business-day period of qualifying closing bid prices (Feb 6–20, 2026).
• Notification Letter received by the company on February 23, 2026; matter indicated as closed by Nasdaq.
• Company issued a press release on February 24, 2026 (filed as Exhibit 99.1 in the 8-K).

Why It Matters

• Regaining compliance removes an immediate delisting risk tied to the minimum bid-price rule and allows ADIL to remain listed on Nasdaq, preserving trading liquidity and access to capital markets.
• This filing does not announce financial results, management changes, or other corporate actions; it solely reports Nasdaq’s determination about bid-price compliance. Investors should note the company remains subject to ongoing listing standards.